Kymera Therapeutics, Inc. (KYMR) stock
KYMRNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 9/30227% above fair value
$121.52−4.33 (-3.44%)
Close on Nov 17, 2026Market cap $10.37BP/E –Yield –
Kymera Therapeutics total assets
Total assets on the balance sheet at the end of each period.
Kymera Therapeutics's total assets was $1.77B at Sep 30, 2026. For fiscal 2025 it was $1.74B, up 78.2% from the year before. The highest annual figure on record is $1.74B in fiscal 2025.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.74B | +78.2% |
| FY2024 | Dec 31, 2024 | $978.04M | +69.9% |
| FY2023 | Dec 31, 2023 | $575.76M | -4.5% |
| FY2022 | Dec 31, 2022 | $603.13M | -0.5% |
| FY2021 | Dec 31, 2021 | $605.91M | +24.4% |
| FY2020 | Dec 31, 2020 | $487.18M | +317.5% |
| FY2019 | Dec 31, 2019 | $116.70M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $1.77B | +60.4% |
| Q2 FY2026 | Jun 30, 2026 | $1.65B | +45.5% |
| Q1 FY2026 | Mar 31, 2026 | $1.67B | +81.7% |
| Q4 FY2025 | Dec 31, 2025 | $1.74B | +78.2% |
| Q3 FY2025 | Sep 30, 2025 | $1.10B | +6.5% |
| Q2 FY2025 | Jun 30, 2025 | $1.13B | +36.9% |
| Q1 FY2025 | Mar 31, 2025 | $918.31M | +5.8% |
| Q4 FY2024 | Dec 31, 2024 | $978.04M | +69.9% |
| Q3 FY2024 | Sep 30, 2024 | $1.03B | +87.3% |
| Q2 FY2024 | Jun 30, 2024 | $826.02M | +41.9% |
| Q1 FY2024 | Mar 31, 2024 | $868.25M | +41.4% |
| Q4 FY2023 | Dec 31, 2023 | $575.76M | -4.5% |
| Q3 FY2023 | Sep 30, 2023 | $552.38M | -13.5% |
| Q2 FY2023 | Jun 30, 2023 | $581.95M | +11.2% |
| Q1 FY2023 | Mar 31, 2023 | $613.91M | +9.0% |
| Q4 FY2022 | Dec 31, 2022 | $603.13M | -0.5% |
| Q3 FY2022 | Sep 30, 2022 | $638.47M | -0.6% |
| Q2 FY2022 | Jun 30, 2022 | $523.42M | +20.5% |
| Q1 FY2022 | Mar 31, 2022 | $563.06M | +21.2% |
| Q4 FY2021 | Dec 31, 2021 | $605.91M | +24.4% |
| Q3 FY2021 | Sep 30, 2021 | $642.45M | +26.6% |
| Q2 FY2021 | Jun 30, 2021 | $434.39M | +272.2% |
| Q1 FY2021 | Mar 31, 2021 | $464.55M | – |
| Q4 FY2020 | Dec 31, 2020 | $487.18M | – |
| Q3 FY2020 | Sep 30, 2020 | $507.36M | – |
| Q4 FY2019 | Dec 31, 2019 | $116.70M | – |
See a number that looks wrong?